Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Roche’s Vabysmo Grabs Top Growth Spot As Sales Decline

Retreats From MAGE-A4 Bispecifics

Executive Summary

The Swiss major’s Q1 earnings show significant growth for Vabysmo, which poses a threat to competitor anti-VEGF drugs from the likes of Novartis and Bayer, even as overall group sales decreased.

You may also be interested in...



Regeneron’s CRL For High-Dose Eylea Benefits Roche, Vabysmo

Although the US FDA complete response letter only cites third-party manufacturing issues, analysts say the delayed approval of 8mg Eylea could continue a competitive advantage for Vabysmo into 2024.

New Therapeutic Areas Ignite Investor Interest Amid Pandemic Reset

Investor attention is turning increasingly to new products and new areas of growth like obesity, Alzheimer’s disease and RSV as big blockbusters face increasing competitive pressure. 

Oculis Eyes Double DIAMOND After Initial Phase III Success In DME

The Swiss firm’s lead candidate has hit the mark in the first stage of a pivotal diabetic macular edema program, edging closer to becoming the first eye drop treatment for a condition where unmet need remains despite the advent of anti-VEGFs.

Related Content

Topics

Related Companies

Latest Headlines
See All
UsernamePublicRestriction

Register

SC148273

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel